These data corroborate previous study in clinical, which have found an enhanced efficacy of HDAC inhibitor combined with carboplatin and paclitaxel in patients with advanced NSCLC.21 In summary, given the limited capacity of paclitaxel to control advanced NSCLC, this work lays the foundation for a promising therapeutic strategy. This evidence concerns the gene HDAC9 and non-small cell lung carcinoma.